Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

TSXV:HEM - Post Discussion

Hemostemix Inc > Hemostemix Announces Partnership and Funding
View:
Post by sdhaka on Jun 04, 2024 2:35pm

Hemostemix Announces Partnership and Funding

Hemostemix Announces Partnership and Funding for ACP-01 Manufacturing


Hemostemix Inc. (HEM) announced a strategic manufacturing partnership with CytoImmune Therapeutics, a private company specializing in clinical manufacturing for biotech firms.


This collaboration involves a Letter of Intent (LOI) to jointly manufacture Hemostemix's lead product, ACP-01. The goal is to provide this investigational treatment to patients with critical needs on a compassionate-use basis.


Compassionate-use programs allow access to unapproved treatments for patients with life-threatening conditions who have no other options.
Read more on this update for free : https://www.researchfrc.com/content/analyst-ideas/post/96/data-backs-our-rate-cut-predictions-time-to-revisit-lithium-stocks

 

*FRC provides issuer-paid coverage.

*Past performance is not indicative of future results.

Be the first to comment on this post
Hemostemix Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested